Darolutamide in Spain: a multicenter review of real-world clinical practice in nmCRPC and mHSPC

Introduction Validating treatments outside clinical trials is crucial to confirm their routine value. Thus, this review examines Spanish real-world data (2022–2025) that show consistent effectiveness and good tolerability of darolutamide in both nmCRPC and mHSPC.Areas covered This structured narrative review summarizes Spanish real-world evidence on darolutamide reported between 2022 and 2025, based on abstracts and posters from national scientific meetings organized by SEOM, SEOR, AEU, GUO, and SEFH. The evidence comprises single-center case series, retrospective observational studies, and multicenter cohorts evaluating darolutamide in nmCRPC and mHSPC. Evidence from observational cohorts involved predominantly elderly patients with relevant comorbidity and frequent polypharmacy. In nmCRPC and mHSPC, biochemical responses were high and meaningful long-term outcomes were observed. Treatment was generally well tolerated, with low reported discontinuation rates. Available observational data do not establish a comparative reduction in drug–drug interactions.Expert opinion Emerging Spanish real-world evidence suggests that the clinical benefits observed with darolutamide in randomized trials may extend to older, medically complex patients with substantial polypharmacy. However, larger prospective studies with longer follow-up are needed to confirm long-term effectiveness, safety, and treatment persistence in routine clinical practice, alongside potential pharmacological advantages.

Authors

Institutions

Publication Details

Journal
Expert Review of Anticancer Therapy
Published
2026-11-19
DOI
https://doi.org/10.1080/14737140.2026.2762697
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Darolutamide in Spain: a multicenter review of real-world clinical practice in nmCRPC and mHSPC

Blanca Tavara Silva, Joel Mases, Sara Álvarez Rodríguez, Oskar Estradé et al.
Expert Review of Anticancer Therapy
Prostate Cancer Treatment and Research
article

Darolutamide in Spain: a multicenter review of real-world clinical practice in nmCRPC and mHSPC

Blanca Tavara Silva, Joel Mases, Sara Álvarez Rodríguez, Oskar Estradé, Antoni Vilaseca, Fernando López‐Campos, Pedro de Pablos‐Rodríguez, Paola Usán Egea, Jorge García Rodríguez, Teresa Alonso Gordoa, Enrique de la Peña, Cristina Moretones Agut, Ana Isabel Serrano Gutiérrez, Luis A. San-José Manso
article en

Abstract

Introduction Validating treatments outside clinical trials is crucial to confirm their routine value. Thus, this review examines Spanish real-world data (2022–2025) that show consistent effectiveness and good tolerability of darolutamide in both nmCRPC and mHSPC.Areas covered This structured narrative review summarizes Spanish real-world evidence on darolutamide reported between 2022 and 2025, based on abstracts and posters from national scientific meetings organized by SEOM, SEOR, AEU, GUO, and SEFH. The evidence comprises single-center case series, retrospective observational studies, and multicenter cohorts evaluating darolutamide in nmCRPC and mHSPC. Evidence from observational cohorts involved predominantly elderly patients with relevant comorbidity and frequent polypharmacy. In nmCRPC and mHSPC, biochemical responses were high and meaningful long-term outcomes were observed. Treatment was generally well tolerated, with low reported discontinuation rates. Available observational data do not establish a comparative reduction in drug–drug interactions.Expert opinion Emerging Spanish real-world evidence suggests that the clinical benefits observed with darolutamide in randomized trials may extend to older, medically complex patients with substantial polypharmacy. However, larger prospective studies with longer follow-up are needed to confirm long-term effectiveness, safety, and treatment persistence in routine clinical practice, alongside potential pharmacological advantages.

Expert Review of Anticancer Therapy
Hospital Universitario Fundación Alcorcón (ES), Fundación Instituto Valenciano de Oncología (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario de La Princesa (ES), Hospital Universitario Central de Asturias (ES), Hospital de Cruces (ES), Hospital Universitario Lucus Augusti (ES), Hospital Universitario Ramón y Cajal (ES), Hospital Universitario de Toledo (ES)
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon